Studies immune cells in bone marrow of myeloma patients receiving BCMA-targeted therapy
Observes immune changes in bone marrow of adults with relapsed myeloma receiving BCMA-targeted treatment.
Plain-language title generated from the registry record
Registry title: Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
Key facts
- Where
- Aarhus, Copenhagen, Gødstrup, Odense, Roskilde, and Vejle, DenmarkSee the 6 sites
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkNo longer taking part
- Copenhagen University HospitalCopenhagen, DenmarkNo longer taking part
- Regional Hospital GødstrupGødstrup, DenmarkNo longer taking part
- Odense University HospitalOdense, DenmarkNo longer taking part
- Zealand University Hospital, RoskildeRoskilde, DenmarkNo longer taking part
- Vejle HospitalVejle, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT07878208
- Record updated
- 16 October 2026
- Original description
The main goal of the project is to characterize the bone marrow immunological milieu and investigate potential treatment defining events of the tumor microenvironment in relapsed and refractory multiple myeloma (RRMM) patients receiving BCMA-targeted therapies.Read full original descriptionShow less
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
The main goal of the project is to characterize the bone marrow immunological milieu and investigate potential treatment defining events of the tumor microenvironment in relapsed and refractory multiple myeloma (RRMM) patients receiving BCMA-targeted therapies.
Inclusion: Signed informed consent form; Participant age ≥ 18 years; Prior diagnosis of multiple myeloma according to the IMWG-criteria; Progressive disease as defined by IMWG during and after treatment with a BCMA-targeted therapy.
Exclusion: Initiated subsequent anti-myeloma treatment before inclusion.